Business Context and Reporting Period
Pasithea Therapeutics Corp. filed a Form 8-K dated October 12, 2022, reporting events occurring primarily on October 11, 2022. The filing concerns the acquisition of AlloMek Therapeutics, LLC, the issuance of securities, and the appointment of a new Chief Financial Officer.
Transaction and Key Financial Terms
- Pasithea acquired 100% of the issued and outstanding equity of AlloMek from its sellers on October 11, 2022.
- Consideration included 2,700,000 shares of Pasithea common stock, 1,000,000 five-year warrants exercisable at $1.88 per share, and $1.05 million in cash.
- The sellers may also receive milestone payments of up to $5.0 million and contingent earn-out payments equal to 3% to 5% of net sales of the applicable drug, depending on sales levels and measurement periods.
- The common stock and warrants were issued in an unregistered transaction relying on the Securities Act Section 4(a)(2) exemption.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, acquisition accounting, or valuation information for AlloMek or the combined company.
Material Changes and Capitalization Effects
- The acquisition adds AlloMek as a wholly owned subsidiary and creates immediate equity dilution from the issuance of 2.7 million common shares, with additional potential dilution from 1.0 million warrants and the CFO option grant.
- Pasithea must file a resale registration statement for the sellers’ shares and shares issuable upon warrant exercise no later than 45 calendar days after filing its 2022 Form 10-K, and must seek effectiveness promptly.
- The sellers entered into two-year lock-up agreements. Restrictions lapse for 1.35 million shares on the first anniversary of closing, followed by monthly releases of 112,500 shares. Additional sales-volume limitations apply for three months after each release.
Management, Compensation, Outlook, and Risks
- Daniel Schneiderman became Chief Financial Officer effective October 11, 2022. He had served as a company consultant since July 1, 2022.
- His employment agreement provides for a $330,000 annual salary, a $30,000 signing bonus, eligibility for an annual milestone bonus, and options to purchase 300,000 shares at an exercise price of $1.26 per share.
- The options vest subject to continued employment: 100,000 shares after 12 months and the remaining 200,000 shares in equal monthly tranches thereafter.
- Upon an involuntary termination other than for cause, the agreement provides six months of salary continuation, six months of COBRA premium payments, a prorated annual bonus, and accelerated vesting of unvested equity awards.
- The acquisition agreement includes customary representations, warranties, indemnification, non-competition, and non-solicitation provisions.
- The filing announces the acquisition but does not provide specific clinical, commercial, revenue, earnings, financing, or operational guidance for AlloMek or Pasithea.
Most Important Facts to Verify
- AlloMek’s assets, drug-development status, intellectual property, clinical data, regulatory requirements, and commercialization prospects.
- The acquisition-date fair value and accounting treatment of the shares, warrants, cash consideration, milestone obligations, and sales-based earn-outs.
- Pasithea’s post-transaction cash balance, liquidity runway, and ability to fund AlloMek’s development programs.
- The number of Pasithea shares outstanding before and after the transaction and the resulting dilution from issued and potentially issuable securities.
- The terms and effectiveness of the required resale registration statement and the timing of lock-up expirations.
- The CFO employment agreement, including the full definitions of cause, good reason, milestones, and termination benefits.